AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24622816
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) performed three times daily for 5 days at a dosage of 1.4 J/cm(2)
Trial: 22297422
Drug: Brucella abortus
RxNorm normalized name: BRUCELLA ABORTUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 4 weeks apart)
Trial: 22297422
Drug: Brucella abortus
RxNorm normalized name: BRUCELLA ABORTUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 18 weeks apart)
Trial: 17451339
Drug: Retroperitoneoscopic nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneoscopic nephrectomy (RN) for giant hydronephrosis (GH); mean operating time 126 minutes (range 65-240 minutes), estimated blood loss 101 mL (range 5-450 mL), mean length of hospital stay 2.9 days (range 1.5-6 days).
Trial: 17451339
Drug: Retroperitoneoscopic nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneoscopic nephrectomy (RN) for small nonfunctioning kidneys (SNFK); mean operating time 116 minutes (range 55-270 minutes), estimated blood loss 46 mL (range 5-400 mL), mean length of stay 2.8 days (range 1-5 days).
Trial: 15694571
Drug: Appropriate care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate care with hylan G-F 20 (AC+H)
Trial: 15694571
Drug: Appropriate care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate care without hylan G-F 20 (AC)
Trial: 779465
Drug: Live, oral,
RxNorm normalized name: Adenovirus Vaccine, Live, Oral, Type 4
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, oral, streptomycin-dependent Shigella sonnei vaccine
Trial: 22950667
Drug: Iota-carrageenan nasal
RxNorm normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iota-carrageenan nasal spray (0.12%)
Trial: 17414581
Drug: Nifedipine microgranules
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine microgranules (NMG) 30 mg/day
Trial: 17414581
Drug: Nifedipine osmotic
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine osmotic pump (NOP) 30 mg/day
Trial: 15992694
Drug: Postoperative regional
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative regional chemotherapy with fluorouracil followed by systemic chemotherapy with fluorouracil and folinic acid (n=368) or with fluorouracil and levamisole (n=380).
Trial: 15992694
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy alone (379 with fluorouracil and folinic acid, and 374 with fluorouracil and levamisole).
Trial: 15992694
Drug: Regional chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional chemotherapy (intraperitoneal or intraportally).
Trial: 15992694
Drug: Non-regional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-regional treatment (systemic chemotherapy alone).
Trial: 15992694
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including both regional and systemic chemotherapy).
Trial: 10472217
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin and gentamicin-vancomycin antibiotic prophylaxis (Group D)
Trial: 10472217
Drug: Cefamandole and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole and high-dose aprotinin (Group B)
Trial: 1833901
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg captopril (C)
Trial: 1833901
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg captopril (C)
Trial: 1833901
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg enoximone (E)
Trial: 1833901
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg enoximone (E)
Trial: 6315025
Drug: suloctidil 200
RxNorm normalized name: suloctidil
DrugBank: Suloctidil (DB13340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suloctidil 200 mg three times per day
Trial: 30137262
Drug: Video-Guided Acupuncture
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-Guided Acupuncture Imagery Treatment (VGAIT)
Trial: 29845877
Drug: AIHA patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIHA patients with partial or no response to therapy (CD8+CD57+ cells frequency)
Trial: 27310905
Drug: More intensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intensive treatment (systolic BP < 120 mmHg)
Trial: 27310905
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive treatment (systolic BP < 140 mmHg)
Trial: 24632748
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with oseltamivir and azithromycin (AZM)
Trial: 12519138
Drug: i.v. buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. buprenorphine 2.5 micro g.kg‐1 (group B)
Trial: 12519138
Drug: caudal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caudal buprenorphine 2.5 micro g.kg‐1 (group C)
Trial: 10354967
Drug: IL-10 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-10 with prednisone (15 mg p.o.)
Trial: 30694918
Drug: TX-001HR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg
Trial: 30694918
Drug: TX-001HR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-001HR (oral estradiol and progesterone capsules) 0.5 mg/100 mg
Trial: 30694918
Drug: TX-001HR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg (phase 1 study)
Trial: 30694918
Drug: TX-001HR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-001HR (oral estradiol and progesterone capsules) 0.5 mg/100 mg (phase 1 study)
Trial: 30694918
Drug: TX-001HR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg and 0.5 mg/100 mg
Trial: 30694918
Drug: TX-001HR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-001HR (oral estradiol and progesterone capsules)
Trial: 28485429
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg PI2
Trial: 28485429
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg PI2
Trial: 25559067
Drug: Lunchtime walks
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lunchtime walks (three weekly 30-min group-led walks for 10 weeks)
Trial: 25559067
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (control period)
Trial: 19825330
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) 2,250 to 3,000 mg/day
Trial: 19825330
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (SH) 4,800 to 6,400 mg/day
Trial: 8422223
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean dose, 5.2 mg, n = 27)
Trial: 8422223
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride (mean dose, 175 mg, n = 11)
Trial: 8422223
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean dose, 8.0 pills, n = 10)
Trial: 8422223
Drug: Alprazolam (follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (follow-up mean daily dose, 6.1 mg vs 1.6 mg, n = 14)
Trial: 8422223
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (8-month completers and study dropouts)
Trial: 31183389
Drug: 48 mg
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mg sucralose dissolved in 60 mL water
Trial: 31183389
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL water as placebo
Trial: 26583672
Drug: Octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide acetate (100 μg) subcutaneously
Trial: 26583672
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline, 1 mL)
Trial: 21639607
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment alliance scores
Trial: 19324125
Drug: Intermittent bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bupivacaine administration (30 mL every 6 hours)
Trial: 19324125
Drug: Continuous bupivacaine
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bupivacaine infusion (5 mL/h)
Trial: 19324125
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no local anesthetic infusion)
Trial: 12634667
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg three times daily
Trial: 3020832
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam administration (10 mg)
Trial: 16707411
Drug: Novel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel matrix transdermal formulation of fentanyl (50 mug/h)
Trial: 16707411
Drug: Conventional reservoir
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional reservoir formulation of fentanyl
Trial: 14504680
Drug: Hydrocortisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (20 mg, administered twice daily for 7 days)
Trial: 11826514
Drug: Brief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intervention to help formulate questions about drug therapy
Trial: 8277179
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg orally twice a day)
Trial: 4274488
Drug: Lumbar rotational
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar rotational manipulation followed by four daily detuned short-wave diathermy sessions (15 minutes each)
Trial: 4274488
Drug: Detuned short-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detuned short-wave diathermy only (five 15-minute daily sessions)
Trial: 25589719
Drug: Nutraceutical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical formulation (NF; folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Trial: 20948588
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with monomeric allergoid (three different shortened up-dosing schedules)
Trial: 20948588
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sublingual immunotherapy, only rescue medications)
Trial: 18371477
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d for 1 year after a 300 mg loading dose before PCI
Trial: 18371477
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d for 28 days and placebo for the remainder of a year after a placebo loading dose at the time of PCI
Trial: 8941027
Drug: Thioridazine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 1.0 mg
Trial: 1327980
Drug: Propranolol (non-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (non-selective beta adrenergic antagonist)
Trial: 1327980
Drug: Atenolol (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (selective beta-1 antagonist)
Trial: 1327980
Drug: Isoprenaline (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (beta adrenoreceptor agonist)
Trial: 3894481
Drug: Albuterol/theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/theophylline
Trial: 31342499
Drug: Health promotion
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health promotion education group activities (90 minutes, twice a week for 8 sessions)
Trial: 31342499
Drug: Routine dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dialysis treatment and nursing care
Trial: 23730808
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training + Testosterone (50-100 mg/d)
Trial: 23730808
Drug: Testosterone only
RxNorm normalized name: Testosterone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone only (50-100 mg/d)
Trial: 16029381
Drug: Epinephrine at
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine at 2 mcg/min
Trial: 16029381
Drug: Norepinephrine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine at 2 mcg/min
Trial: 12874742
Drug: Oral kilocalorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral kilocalorie and protein supplementation for 3 months (treatment group)
Trial: 12874742
Drug: Oral kilocalorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral kilocalorie and protein supplementation (treatment group)
Trial: 2146231
Drug: Trospectomycin 250
RxNorm normalized name: TROSPECTOMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospectomycin 250 mg
Trial: 2146231
Drug: Trospectomycin 500
RxNorm normalized name: TROSPECTOMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospectomycin 500 mg
Trial: 2146231
Drug: Trospectomycin 750
RxNorm normalized name: TROSPECTOMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospectomycin 750 mg
Trial: 31931884
Drug: LINC‐II intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LINC‐II intervention (strengths‐based HIV case management, rapid ART initiation, pharmacotherapy for opioid use disorder)
Trial: 9110007
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac (1 mg/kg)
Trial: 3543161
Drug: Acedapsone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acedapsone (3 injections at 10 weeks interval)
Trial: 3543161
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 injections at 10 weeks interval)
Trial: 29362929
Drug: Multimodal ADHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal ADHD treatment (group psychotherapy plus methylphenidate)
Trial: 25523036
Drug: ORAL IMPACT®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL IMPACT® (preoperative oral immunonutrition)
Trial: 25523036
Drug: IMPACT CONTROL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPACT CONTROL® (isocaloric isonitrogenous supplement)
Trial: 21880080
Drug: Lactulose (L)
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose (L)
Trial: 18296130
Drug: Intravenous prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone, 40-60 mg/day for 5-10 days (n = 35)
Trial: 16158009
Drug: DemTect cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DemTect cutoff score of ≤13 points for AD-typical patterns of cerebral glucose metabolism
Trial: 11843742
Drug: Intranasal PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal PCA diamorphine (1.0 mg bolus, 3 min lockout)
Trial: 11843742
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA diamorphine (0.5 mg bolus, 3 min lockout)
Trial: 29667211
Drug: Celecoxib 100-200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100-200 mg b.d.
Trial: 29667211
Drug: Ibuprofen 600-800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600-800 mg t.d.s.
Trial: 29667211
Drug: Naproxen 375-500
RxNorm normalized name: naproxen 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 375-500 mg b.d.
Trial: 20716305
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg per week of oral naltrexone plus standard psychosocial treatment as usual (n = 56)
Trial: 20716305
Drug: Standard psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychosocial treatment as usual (TAU) without naltrexone (n = 55)
Trial: 12021498
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal CRM 197 conjugate vaccine
Trial: 9042984
Drug: Alginate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate (2 x 250 mg chewable tablets)
Trial: 7836717
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (four doses)
Trial: 29550020
Drug: Topical dipyrone
RxNorm normalized name: dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dipyrone gel
Trial: 23656980
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin glargine
Trial: 20158586
Drug: sulfasalazine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfasalazine (maximum 2.5 g/day)
Trial: 17012867
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever 17D vaccine
Trial: 11783327
Drug: HANS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HANS plus small dose of buprenorphine (BPN)
Trial: 9595795
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration by nasal cannula during the first or second postoperative night
Trial: 9595795
Drug: No oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oxygen therapy (control group)
Trial: 8357297
Drug: Alprazolam (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (titrated upward to reach 6.0 mg/d)
Trial: 2877953
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per day dihydroergotamine
Trial: 31410765
Drug: Lozenges containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenges containing Lactobacillus reuteri taken twice daily for 90 days
Trial: 21451152
Drug: EZG(RTG) 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZG(RTG) 1,200 mg/day
Trial: 15301297
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food challenges (cow milk, hen egg, wheat)
Trial: 8996417
Drug: USA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USA treatment
Trial: 8996417
Drug: Other countries
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other countries treatment
Trial: 8491245
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg (Group 1, n = 6)
Trial: 8491245
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg (Group 2, n = 6)
Trial: 8491245
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg (Group 2) with addition of Nifedipine
Trial: 8491245
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg (Group 2)
Trial: 26755229
Drug: Colloid preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid preload with 0.5 L of 6% w/v hydroxyethyl starch solution
Trial: 26755229
Drug: Prophylactic IV
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic IV infusion of 15 mg ephedrine
Trial: 16641468
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (Boost Plus)
Trial: 10026369
Drug: Continuous 6-ppm
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 6-ppm dose of inhaled nitric oxide (iNO)